HP
CMPX icon

HealthInvest Partners’s Compass Therapeutics CMPX Stock Holding History

HealthInvest Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
1,048,593
+1,006,762
+2,407% +$2.97M 0.62% 38
2026
Q1 		$3.05M Sell
41,831
-542,501
-93% -$3.13M 0.99% 34
2025
Q4 		$3.14M Buy
+584,332
New +$2.7M 1% 32

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HealthInvest Partners's CMPX Position: Q2 2026 in Review

HealthInvest Partners increased its Compass Therapeutics (CMPX) stake by 2,407% in Q2 2026, buying an estimated $2.97M and bringing the position to 1,048,593 shares worth $2.3M. The position accounts for 0.62% of the portfolio, ranked #38.

HealthInvest Partners first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.14M in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • HealthInvest Partners held 1,048,593 shares of Compass Therapeutics worth $2.3M as of Q2 2026.
  • HealthInvest Partners bought 1,006,762 Compass Therapeutics shares in Q2 2026, an estimated $2.97M.
  • Compass Therapeutics made up 0.62% of HealthInvest Partners's portfolio in Q2 2026, its #38 holding.
  • HealthInvest Partners first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • HealthInvest Partners's Compass Therapeutics position peaked at $3.14M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on HealthInvest Partners's 13F filing for Q2 2026, filed 24 Jul 2026.